Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
Qiagen announced plans for global launches of tuberculosis and molecular diagnostic tests developed with two separate companies.
In two studies, researchers used machine learning to spot and classify cells—as well as their hidden, internal structures and DNA—using images alone.
The e-clinical market is crowded with a variety of vendors that seemingly perform similar tasks. Learn how to assess and evaluate the differences.
Akili Interactive licensed new software from UCSF that combines physical activity with programs targeting neural systems to cognitive function.
The FDA approved Biotronik’s stent to seal tears in coronary arteries, making it the first new treatment option in the indication in 17 years.
Clinical research sites have a tough, but critically important, job. It’s rigorous and precise work, but essential to the progress of medicine.
This year, we’re hoping to continue spotlighting the most innovative and promising private startups in the medtech industry, and we need your help.
Cancer blood test company Epic Sciences raised $52 million to move its treatment-guiding liquid biopsies toward regulatory approval.
XACT Robotics raised $5 million alongside a CE mark for its integrated robotic system for image-guided, needle-puncture procedures, such as biopsies.
Acorda’s share price took a one-two punch this week, with the FDA extending review of its drug-device treatment for Parkinson’s disease by 3 months.
Endotronix raised $45 million to fund development of its Cordella wireless, implantable pulmonary artery sensor.
Amgen has tapped Deloitte to build the foundation of its global digital patient services strategy.